Revolutionizing Cellular Therapy for Solid Tumors
Harnessing genetic engineering and AI, TriaCyte helps bring your cell therapies to solid tumors, boosting efficacy while reducing development time and cost

At the frontier of science and technology, we empower cell therapies to tackle hard-to-treat solid tumors.
Homing

Engineered immune cells guided with precision to locate and reach solid tumors
Infiltration

Specialized designs that enable immune cells to penetrate dense tumor environments
AIāDriven Design

Apply artificial intelligence for smarter CAR and immune cells selection
Our Team
Akram Obiedat, Phd

Co-founder and CEO
Akram leads TriaCyte's strategic vision, business development, and translational efforts to advance next-generation cell therapies for solid tumors. He holds a PhD in Immunology and Pharmacology and brings over six years of experience in immunotherapy development.
Nour Atamni

Co-founder and CTO
Nour leads TriaCyte's AI-driven computational platform, integrating machine learning and biological insights to engineer next-generation proteins for immune cell therapies. He is a PhD candidate in Computer Science at Ben-Gurion University, specializing in artificial intelligence.
Scientific Advisory Board
Professor of Medicine
Director, Cancer Institute Program in Cellular Immunotherapy
Harvard Medical School
Mass General Brigham Cancer Institute
Professor of Medicine
Scientific Co-Director, Cell Therapy and Transplant Program
āHospital of the University of Pennsylvania



